The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 6, 2012, Pages 712-718

  Monteiro, T P ^a   El Jaick, K B ^a   Jeovanio Silva, A L ^a   Brasil, P E A A ^a   Costa, M J M ^a   Rolla, V C ^a   De Castro, L ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

adverse event; drug related; genetic polymorphisms; pharmacogenetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; GENOMIC DNA; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; TUBERCULOSTATIC AGENT; VITAMIN D RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GENE DELETION; GENOTYPE; HEPATITIS B; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; TOXIC HEPATITIS;

ADULT; ANTITUBERCULAR AGENTS; BRAZIL; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 84868383094     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01368.x     Document Type: Article

References (27)

1. Leiro V, Fernández-Villar A, Valverde D, Constenla L, Vázquez R, Piñeiro L, González-Quintela A,. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int, 2008; 28: 835-839.
2. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R,. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol, 2008; 23: 192-202.
3. Leung CC, Chan CK, Tam CM,. HIV-related TB and adverse drug events. Thorax, 2007; 62: 923-924.
4. Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis, 2010; 50: 833-839.
5. Eaton DL, Bammler TK,. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci, 1999; 49: 156-164.
6. Lucena MI, Andrade RJ, Martinez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology, 2008; 48: 588-596.
7. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP,. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol, 2001; 16: 1033-1037.
8. Xu S, Wang Y, Roe B, Pearson WR,. Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion. J Biol Chem, 1998; 273: 3517-3527.
9. Sodhi CP, Rana S, Mehta S, Vaiphei K, Goel RC, Mehta SK,. Study of oxidative-stress in rifampicin-induced hepatic injury in growing rats with and without protein-energy malnutrition. Hum Exp Toxicol, 1997; 16: 315-321.
10. Sodhi CP, Rana SV, Mehta SK, Vaiphei K, Attri S, Thakur S, Mehta S,. Study of oxidative stress in isoniazid-induced hepatic injury in young rats with and without protein-energy malnutrition. J Biochem Toxicol, 1996; 11: 139-146.
11. Chatterjee S, Lyle N, Mandal A, Kundu S,. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther, 2010; 35: 465-470.
12. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, Lee SD,. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol, 2007; 47: 128-134.
13. Kim SH, Kim SH, Yoon HJ, et al. GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans. Tuberculosis (Edinb), 2010; 90: 39-43.
14. Mayfield D, McLeod G, Hall P,. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry, 1974; 131: 1121-1123.
15. Arand M, Mühlbauer R, Hengstler J, Jäger E, Fuchs J, Winkler L, Oesch F,. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem, 1996; 236: 184-186.
16. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.
17. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
18. de Castro L, do Brasil PE, Monteiro TP, Rolla VC,. Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule Int J Tuberc Lung Dis, 2010; 14: 332-340.
19. Roy PD, Majumder M, Roy B,. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics, 2008; 9: 311-321.
20. Suarez-Kurtz G, Vargens DD, Struchiner CJ, Bastos-Rodrigues L, Pena SD,. Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenet Genomics, 2007; 17: 765-771.
21. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. Aids, 2001; 15: 1261-1268.
22. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD,. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc, 2000; 283: 74-80.
23. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF,. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS, 2009; 20: 339-345.
24. Wanchu A, Rana SV, Pallikkuth S, Sachdeva RK,. Short communication: oxidative stress in HIV-infected individuals: a cross-sectional study. AIDS Res Hum Retroviruses, 2009; 25: 1307-1311.
25. Roodi N, Dupont WD, Moore JH, Parl FF,. Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk. Cancer Res, 2004; 64: 1233-1236.
26. Yu KD, Di GH, Fan L, et al. A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB J, 2009; 23: 2274-2287.
27. Teixeira RL, Morato RG, Cabello PH, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz, 2011; 106: 716-724.